These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20189446)

  • 21. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cutaneous side effects of EGF-receptor inhibition and their management].
    Gutzmer R; Werfel T; Kapp A; Elsner J
    Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
    Requena C; Llombart B; Sanmartín O
    Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis.
    Tomková H; Pospíšková M; Zábojníková M; Kohoutek M; Serclová M; Gharibyar M; Sternberský J
    J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):514-9. PubMed ID: 22035385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-EGFR monoclonal antibody-induced hypomagnesaemia.
    Fakih M
    Lancet Oncol; 2007 May; 8(5):366-7. PubMed ID: 17466890
    [No Abstract]   [Full Text] [Related]  

  • 27. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging therapies in head and neck cancers: EGFR inhibitors.
    Held-Warmkessel J
    ONS News; 2006; 21(8 Suppl):61-2. PubMed ID: 16925156
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
    Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nimotuzumab: evidence of clinical benefit without rash.
    Allan DG
    Oncologist; 2005 Oct; 10(9):760-1. PubMed ID: 16249358
    [No Abstract]   [Full Text] [Related]  

  • 31. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
    Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
    Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
    Moon C; Chae YK; Lee J
    Exp Biol Med (Maywood); 2010 Aug; 235(8):907-20. PubMed ID: 20562132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer.
    Kim S; Grandis JR; Rinaldo A; Takes RP; Ferlito A
    Head Neck; 2008 May; 30(5):667-74. PubMed ID: 18383530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials.
    Bauer KA; Hammerman S; Rapoport B; Lacouture ME
    Clin Colorectal Cancer; 2008 Sep; 7(5):309-14. PubMed ID: 18794062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
    Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
    Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
    Ouwerkerk J; Boers-Doets C
    Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
    You B; Chen EX
    J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. More on cetuximab in head and neck cancer.
    Mell LK; Weichselbaum RR
    N Engl J Med; 2007 Nov; 357(21):2201-2; author reply 2202-3. PubMed ID: 18032774
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of a pre-emptive skin treatment regimen on skin toxicities of anti-epidermal growth factor receptor monoclonal antibodies: more questions than answers.
    Rother M
    J Clin Oncol; 2010 Sep; 28(27):e474; author reply e475-6. PubMed ID: 20585089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.